ArticleTranslational cancer research2026
Lysosome-dependent cell death reveals a prognostic signature in colorectal cancer via integrated analysis of scRNA-seq and bulk RNA-seq data.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is one of the most common vulgar malignancies worldwide. Recent researches have displayed that lysosomes, important intracellular degradation and signal transduction centers, dramatically affect cancer occurrence and development via regulating proliferation, metabolism, programmed death and other key biological processes. Lysosomes significantly influence CRC progression by regulating biological processes such as programmed cell death. This study aims to develop a lysosome-dependent cell death (LDCD)-based prognostic signature to predict survival and immunotherapy efficacy in CRC patients. Methods: In our work, we innovatively incorporated single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (bulk RNA-seq) data to establish an LDCD activity evaluation system and systematically analyzed the dynamic changes in LDCD activity during the differentiation trajectory of tumor cells and its interaction with tumor microenvironment (TME). Results: We observed that high-LDCD-producing tumor cells were present mainly in the initial stage of CRC differentiation via single-cell trajectory analysis. Further cell communication network analysis revealed significantly different interaction patterns between tumor cell subsets with different LDCD activities and TME components. A prognostic signature composed of key LDCD-pertaining genes was constructed based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) multicenter cohort data. Validation analysis indicated that the prognostic signature effectively stratified patients into different risk groups, and high- and low-risk groups presented huge disparities in overall survival, immune microenvironment characteristics, treatment sensitivity and immunotherapy response. Conclusions: This study characterizes the spatiotemporal heterogeneity of LDCD activity in CRC from a single-cell perspective. The identified prognostic markers act as independent clinical indicators and furnish a critical theoretical foundation and potential therapeutic targets for advancing personalized CRC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.